Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 123

1.

RAB27A promotes melanoma cell invasion and metastasis via regulation of pro-invasive exosomes.

Guo D, Lui GYL, Lai SL, Wilmott JS, Tikoo S, Jackett LA, Quek C, Brown DL, Sharp DM, Kwan RYQ, Chacon D, Wong JH, Beck D, van Geldermalsen M, Holst J, Thompson JF, Mann GJ, Scolyer RA, Stow JL, Weninger W, Haass NK, Beaumont KA.

Int J Cancer. 2019 Jun 15;144(12):3070-3085. doi: 10.1002/ijc.32064. Epub 2019 Jan 3.

PMID:
30556600
2.

Clearance in Drug Design.

Smith DA, Beaumont K, Maurer TS, Di L.

J Med Chem. 2019 Mar 14;62(5):2245-2255. doi: 10.1021/acs.jmedchem.8b01263. Epub 2018 Oct 17.

PMID:
30281973
3.

Discovery of a Novel Small-Molecule Modulator of C-X-C Chemokine Receptor Type 7 as a Treatment for Cardiac Fibrosis.

Menhaji-Klotz E, Hesp KD, Londregan AT, Kalgutkar AS, Piotrowski DW, Boehm M, Song K, Ryder T, Beaumont K, Jones RM, Atkinson K, Brown JA, Litchfield J, Xiao J, Canterbury DP, Burford K, Thuma BA, Limberakis C, Jiao W, Bagley SW, Agarwal S, Crowell D, Pazdziorko S, Ward J, Price DA, Clerin V.

J Med Chem. 2018 Apr 26;61(8):3685-3696. doi: 10.1021/acs.jmedchem.8b00190. Epub 2018 Apr 17.

PMID:
29627981
4.

HDAC inhibitors restore BRAF-inhibitor sensitivity by altering PI3K and survival signalling in a subset of melanoma.

Gallagher SJ, Gunatilake D, Beaumont KA, Sharp DM, Tiffen JC, Heinemann A, Weninger W, Haass NK, Wilmott JS, Madore J, Ferguson PM, Rizos H, Hersey P.

Int J Cancer. 2018 May 1;142(9):1926-1937. doi: 10.1002/ijc.31199. Epub 2017 Dec 20.

5.

Relevance of Half-Life in Drug Design.

Smith DA, Beaumont K, Maurer TS, Di L.

J Med Chem. 2018 May 24;61(10):4273-4282. doi: 10.1021/acs.jmedchem.7b00969. Epub 2017 Nov 17.

PMID:
29112446
6.

Liver-Targeted Small-Molecule Inhibitors of Proprotein Convertase Subtilisin/Kexin Type 9 Synthesis.

McClure KF, Piotrowski DW, Petersen D, Wei L, Xiao J, Londregan AT, Kamlet AS, Dechert-Schmitt AM, Raymer B, Ruggeri RB, Canterbury D, Limberakis C, Liras S, DaSilva-Jardine P, Dullea RG, Loria PM, Reidich B, Salatto CT, Eng H, Kimoto E, Atkinson K, King-Ahmad A, Scott D, Beaumont K, Chabot JR, Bolt MW, Maresca K, Dahl K, Arakawa R, Takano A, Halldin C.

Angew Chem Int Ed Engl. 2017 Dec 18;56(51):16218-16222. doi: 10.1002/anie.201708744. Epub 2017 Nov 24.

PMID:
29073340
7.

Discovery of Potent and Orally Bioavailable Macrocyclic Peptide-Peptoid Hybrid CXCR7 Modulators.

Boehm M, Beaumont K, Jones R, Kalgutkar AS, Zhang L, Atkinson K, Bai G, Brown JA, Eng H, Goetz GH, Holder BR, Khunte B, Lazzaro S, Limberakis C, Ryu S, Shapiro MJ, Tylaska L, Yan J, Turner R, Leung SSF, Ramaseshan M, Price DA, Liras S, Jacobson MP, Earp DJ, Lokey RS, Mathiowetz AM, Menhaji-Klotz E.

J Med Chem. 2017 Dec 14;60(23):9653-9663. doi: 10.1021/acs.jmedchem.7b01028. Epub 2017 Oct 30.

8.

Real-Time Cell Cycle Imaging in a 3D Cell Culture Model of Melanoma.

Spoerri L, Beaumont KA, Anfosso A, Haass NK.

Methods Mol Biol. 2017;1612:401-416. doi: 10.1007/978-1-4939-7021-6_29.

PMID:
28634959
9.

A cross-species translational pharmacokinetic-pharmacodynamic evaluation of core body temperature reduction by the TRPM8 blocker PF-05105679.

Gosset JR, Beaumont K, Matsuura T, Winchester W, Attkins N, Glatt S, Lightbown I, Ulrich K, Roberts S, Harris J, Mesic E, van Steeg T, Hijdra D, van der Graaf PH.

Eur J Pharm Sci. 2017 Nov 15;109S:S161-S167. doi: 10.1016/j.ejps.2017.06.009. Epub 2017 Jun 7.

PMID:
28603038
10.

Efficient Liver Targeting by Polyvalent Display of a Compact Ligand for the Asialoglycoprotein Receptor.

Sanhueza CA, Baksh MM, Thuma B, Roy MD, Dutta S, Préville C, Chrunyk BA, Beaumont K, Dullea R, Ammirati M, Liu S, Gebhard D, Finley JE, Salatto CT, King-Ahmad A, Stock I, Atkinson K, Reidich B, Lin W, Kumar R, Tu M, Menhaji-Klotz E, Price DA, Liras S, Finn MG, Mascitti V.

J Am Chem Soc. 2017 Mar 8;139(9):3528-3536. doi: 10.1021/jacs.6b12964. Epub 2017 Feb 23.

PMID:
28230359
11.

In Vitro-In Vivo Extrapolation of Intestinal Availability for Carboxylesterase Substrates Using Portal Vein-Cannulated Monkey.

Trapa PE, Beaumont K, Atkinson K, Eng H, King-Ahmad A, Scott DO, Maurer TS, Di L.

J Pharm Sci. 2017 Mar;106(3):898-905. doi: 10.1016/j.xphs.2016.12.001. Epub 2016 Dec 18.

PMID:
27998705
12.

Micropatterning Facilitates the Long-Term Growth and Analysis of iPSC-Derived Individual Human Neurons and Neuronal Networks.

Burbulla LF, Beaumont KG, Mrksich M, Krainc D.

Adv Healthc Mater. 2016 Aug;5(15):1894-903. doi: 10.1002/adhm.201500900. Epub 2016 Apr 24.

13.

Cell Cycle Phase-Specific Drug Resistance as an Escape Mechanism of Melanoma Cells.

Beaumont KA, Hill DS, Daignault SM, Lui GYL, Sharp DM, Gabrielli B, Weninger W, Haass NK.

J Invest Dermatol. 2016 Jul;136(7):1479-1489. doi: 10.1016/j.jid.2016.02.805. Epub 2016 Mar 10.

14.

Clinical Micro-Dose Studies to Explore the Human Pharmacokinetics of Four Selective Inhibitors of Human Nav1.7 Voltage-Dependent Sodium Channels.

Jones HM, Butt RP, Webster RW, Gurrell I, Dzygiel P, Flanagan N, Fraier D, Hay T, Iavarone LE, Luckwell J, Pearce H, Phipps A, Segelbacher J, Speed B, Beaumont K.

Clin Pharmacokinet. 2016 Jul;55(7):875-887. doi: 10.1007/s40262-015-0365-0.

PMID:
26895021
15.

Imaging- and Flow Cytometry-based Analysis of Cell Position and the Cell Cycle in 3D Melanoma Spheroids.

Beaumont KA, Anfosso A, Ahmed F, Weninger W, Haass NK.

J Vis Exp. 2015 Dec 28;(106):e53486. doi: 10.3791/53486.

16.

Discovery of a Selective TRPM8 Antagonist with Clinical Efficacy in Cold-Related Pain.

Andrews MD, Af Forselles K, Beaumont K, Galan SR, Glossop PA, Grenie M, Jessiman A, Kenyon AS, Lunn G, Maw G, Owen RM, Pryde DC, Roberts D, Tran TD.

ACS Med Chem Lett. 2015 Jan 30;6(4):419-24. doi: 10.1021/ml500479v. eCollection 2015 Apr 9.

17.

Volume of Distribution in Drug Design.

Smith DA, Beaumont K, Maurer TS, Di L.

J Med Chem. 2015 Aug 13;58(15):5691-8. doi: 10.1021/acs.jmedchem.5b00201. Epub 2015 Apr 1.

PMID:
25799158
18.

Inhibition of TRPM8 channels reduces pain in the cold pressor test in humans.

Winchester WJ, Gore K, Glatt S, Petit W, Gardiner JC, Conlon K, Postlethwaite M, Saintot PP, Roberts S, Gosset JR, Matsuura T, Andrews MD, Glossop PA, Palmer MJ, Clear N, Collins S, Beaumont K, Reynolds DS.

J Pharmacol Exp Ther. 2014 Nov;351(2):259-69. doi: 10.1124/jpet.114.216010. Epub 2014 Aug 14.

PMID:
25125580
19.

Real-time cell cycle imaging during melanoma growth, invasion, and drug response.

Haass NK, Beaumont KA, Hill DS, Anfosso A, Mrass P, Munoz MA, Kinjyo I, Weninger W.

Pigment Cell Melanoma Res. 2014 Sep;27(5):764-76. doi: 10.1111/pcmr.12274. Epub 2014 Jun 27.

PMID:
24902993
20.

Phenotypic differences in hiPSC NPCs derived from patients with schizophrenia.

Brennand K, Savas JN, Kim Y, Tran N, Simone A, Hashimoto-Torii K, Beaumont KG, Kim HJ, Topol A, Ladran I, Abdelrahim M, Matikainen-Ankney B, Chao SH, Mrksich M, Rakic P, Fang G, Zhang B, Yates JR 3rd, Gage FH.

Mol Psychiatry. 2015 Mar;20(3):361-8. doi: 10.1038/mp.2014.22. Epub 2014 Apr 1.

21.

Targeting glutamine transport to suppress melanoma cell growth.

Wang Q, Beaumont KA, Otte NJ, Font J, Bailey CG, van Geldermalsen M, Sharp DM, Tiffen JC, Ryan RM, Jormakka M, Haass NK, Rasko JE, Holst J.

Int J Cancer. 2014 Sep 1;135(5):1060-71. doi: 10.1002/ijc.28749. Epub 2014 Feb 17.

22.

Correlation between chemotype-dependent binding conformations of HSP90α/β and isoform selectivity-Implications for the structure-based design of HSP90α/β selective inhibitors for treating neurodegenerative diseases.

Ernst JT, Liu M, Zuccola H, Neubert T, Beaumont K, Turnbull A, Kallel A, Vought B, Stamos D.

Bioorg Med Chem Lett. 2014 Jan 1;24(1):204-8. doi: 10.1016/j.bmcl.2013.11.036. Epub 2013 Nov 23.

PMID:
24332488
23.

Mesenchymal cells hold the key to immune cell recruitment to and migration within melanoma.

Beaumont KA, Munoz MA, Weninger W.

J Invest Dermatol. 2013 Sep;133(9):2138-40. doi: 10.1038/jid.2013.206.

24.

Plectin-containing, centrally localized focal adhesions exert traction forces in primary lung epithelial cells.

Eisenberg JL, Beaumont KG, Takawira D, Hopkinson SB, Mrksich M, Budinger GR, Jones JC.

J Cell Sci. 2013 Aug 15;126(Pt 16):3746-55. doi: 10.1242/jcs.128975. Epub 2013 Jun 7.

25.

Multiphase myrmecochory: the roles of different ant species and effects of fire.

Beaumont KP, Mackay DA, Whalen MA.

Oecologia. 2013 Jul;172(3):791-803. doi: 10.1007/s00442-012-2534-2. Epub 2013 Feb 6.

PMID:
23386041
26.

Modeling Melanoma In Vitro and In Vivo.

Beaumont KA, Mohana-Kumaran N, Haass NK.

Healthcare (Basel). 2013 Dec 23;2(1):27-46. doi: 10.3390/healthcare2010027. Review.

27.

Parent and child fluency in a common language: implications for the parent-child relationship and later academic success in Mexican American families.

Schofield T, Beaumont K, Widaman K, Jochem R, Robins R, Conger R.

J Fam Psychol. 2012 Dec;26(6):869-79. doi: 10.1037/a0030423.

28.

PTEN protein expression in malignant pleural mesothelioma.

Agarwal V, Campbell A, Beaumont KL, Cawkwell L, Lind MJ.

Tumour Biol. 2013 Apr;34(2):847-51. doi: 10.1007/s13277-012-0615-9. Epub 2012 Dec 15.

PMID:
23242608
29.

Standardising for reliability: the contribution of tools and checklists.

Beaumont K, Russell J.

Nurs Stand. 2012 Apr 25-May 1;26(34):35-9.

PMID:
22787872
30.

The mechanostability of isolated focal adhesions is strongly dependent on pH.

Beaumont KG, Mrksich M.

Chem Biol. 2012 Jun 22;19(6):711-20. doi: 10.1016/j.chembiol.2012.04.016.

31.

Melanocortin-1 receptor-mediated signalling pathways activated by NDP-MSH and HBD3 ligands.

Beaumont KA, Smit DJ, Liu YY, Chai E, Patel MP, Millhauser GL, Smith JJ, Alewood PF, Sturm RA.

Pigment Cell Melanoma Res. 2012 May;25(3):370-4. doi: 10.1111/j.1755-148X.2012.00990.x. Epub 2012 Mar 19.

32.

The discovery of UK-369003, a novel PDE5 inhibitor with the potential for oral bioavailability and dose-proportional pharmacokinetics.

Rawson DJ, Ballard S, Barber C, Barker L, Beaumont K, Bunnage M, Cole S, Corless M, Denton S, Ellis D, Floc'h M, Foster L, Gosset J, Holmwood F, Lane C, Leahy D, Mathias J, Maw G, Million W, Poinsard C, Price J, Russel R, Street S, Watson L.

Bioorg Med Chem. 2012 Jan 1;20(1):498-509. doi: 10.1016/j.bmc.2011.10.022. Epub 2011 Oct 24.

PMID:
22100260
33.

Case studies addressing human pharmacokinetic uncertainty using a combination of pharmacokinetic simulation and alternative first in human paradigms.

Harrison A, Gardner I, Hay T, Dickins M, Beaumont K, Phipps A, Purkins L, Allan G, Christian R, Duckworth J, Gurrell I, Kempshall S, Savage M, Seymour M, Simpson M, Taylor L, Turnpenny P.

Xenobiotica. 2012 Jan;42(1):57-74. doi: 10.3109/00498254.2011.622418. Epub 2011 Oct 12.

PMID:
21992032
34.

Toward an integrated human clearance prediction strategy that minimizes animal use.

Beaumont K, Gardner I, Chapman K, Hall M, Rowland M.

J Pharm Sci. 2011 Oct;100(10):4518-35. doi: 10.1002/jps.22635. Epub 2011 Jun 24.

PMID:
21710508
35.

The recycling endosome protein Rab17 regulates melanocytic filopodia formation and melanosome trafficking.

Beaumont KA, Hamilton NA, Moores MT, Brown DL, Ohbayashi N, Cairncross O, Cook AL, Smith AG, Misaki R, Fukuda M, Taguchi T, Sturm RA, Stow JL.

Traffic. 2011 May;12(5):627-43. doi: 10.1111/j.1600-0854.2011.01172.x. Epub 2011 Feb 25.

36.

Melanocortin MC₁ receptor in human genetics and model systems.

Beaumont KA, Wong SS, Ainger SA, Liu YY, Patel MP, Millhauser GL, Smith JJ, Alewood PF, Leonard JH, Sturm RA.

Eur J Pharmacol. 2011 Jun 11;660(1):103-10. doi: 10.1016/j.ejphar.2010.11.040. Epub 2011 Jan 1. Review.

37.

Immunological fingerprinting method for differentiation of serum samples in research-oriented biobanks.

Beaumont K, Betsou F.

Clin Vaccine Immunol. 2010 May;17(5):735-40. doi: 10.1128/CVI.00499-09. Epub 2010 Feb 17.

39.

Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches.

Hosea NA, Collard WT, Cole S, Maurer TS, Fang RX, Jones H, Kakar SM, Nakai Y, Smith BJ, Webster R, Beaumont K.

J Clin Pharmacol. 2009 May;49(5):513-33. doi: 10.1177/0091270009333209. Epub 2009 Mar 19.

PMID:
19299532
40.

Does human pharmacokinetic prediction add significant value to compound selection in drug discovery research?

Beaumont K, Smith DA.

Curr Opin Drug Discov Devel. 2009 Jan;12(1):61-71.

PMID:
19152214
41.

The melanocortin-1 receptor gene polymorphism and association with human skin cancer.

Beaumont KA, Liu YY, Sturm RA.

Prog Mol Biol Transl Sci. 2009;88:85-153. doi: 10.1016/S1877-1173(09)88004-6. Epub 2009 Oct 7. Review.

PMID:
20374726
42.

PPARgamma agonists attenuate proliferation and modulate Wnt/beta-catenin signalling in melanoma cells.

Smith AG, Beaumont KA, Smit DJ, Thurber AE, Cook AL, Boyle GM, Parsons PG, Sturm RA, Muscat GE.

Int J Biochem Cell Biol. 2009 Apr;41(4):844-52. doi: 10.1016/j.biocel.2008.08.037. Epub 2008 Sep 6.

PMID:
18822385
43.

Deterioration in hospital patients: early signs and appropriate actions.

Beaumont K, Luettel D, Thomson R.

Nurs Stand. 2008 Sep 10-16;23(1):43-8.

PMID:
18814476
44.

Small, non-peptide C5a receptor antagonists: part 1.

Blagg J, Mowbray C, Pryde DC, Salmon G, Schmid E, Fairman D, Beaumont K.

Bioorg Med Chem Lett. 2008 Oct 15;18(20):5601-4. doi: 10.1016/j.bmcl.2008.08.106. Epub 2008 Aug 31.

PMID:
18809326
45.

Small, non-peptide C5a receptor antagonists: part 2.

Blagg J, Mowbray C, Pryde D, Salmon G, Fairman D, Schmid E, Beaumont K.

Bioorg Med Chem Lett. 2008 Oct 15;18(20):5605-8. doi: 10.1016/j.bmcl.2008.08.101. Epub 2008 Aug 31.

PMID:
18804369
46.

Red hair is the null phenotype of MC1R.

Beaumont KA, Shekar SN, Cook AL, Duffy DL, Sturm RA.

Hum Mutat. 2008 Aug;29(8):E88-94. doi: 10.1002/humu.20788.

PMID:
18484624
47.

Discovery of potent & selective inhibitors of activated thrombin-activatable fibrinolysis inhibitor for the treatment of thrombosis.

Bunnage ME, Blagg J, Steele J, Owen DR, Allerton C, McElroy AB, Miller D, Ringer T, Butcher K, Beaumont K, Evans K, Gray AJ, Holland SJ, Feeder N, Moore RS, Brown DG.

J Med Chem. 2007 Nov 29;50(24):6095-103. Epub 2007 Nov 9.

PMID:
17990866
48.

Cyclization of the acyl glucuronide metabolite of a neutral endopeptidase inhibitor to an electrophilic glutarimide: synthesis, reactivity, and mechanistic analysis.

Meng X, Maggs JL, Pryde DC, Planken S, Jenkins RE, Peakman TM, Beaumont K, Kohl C, Park BK, Stachulski AV.

J Med Chem. 2007 Nov 29;50(24):6165-76. Epub 2007 Nov 7.

PMID:
17985860
49.
50.

Receptor function, dominant negative activity and phenotype correlations for MC1R variant alleles.

Beaumont KA, Shekar SN, Newton RA, James MR, Stow JL, Duffy DL, Sturm RA.

Hum Mol Genet. 2007 Sep 15;16(18):2249-60. Epub 2007 Jul 5. Erratum in: Hum Mol Genet. 2007 Dec 1;16(23):2988. Shekar, Sri L [corrected to Shekar, Sri N].

PMID:
17616515

Supplemental Content

Loading ...
Support Center